Gail Matthews
Biographic Data
| ID | 4980317 |
|---|---|
| NAME | Gail Matthews |
| GIVEN NAMES | Gail |
| FAMILY NAME | Matthews |
| SIGNATURE | MATTHEWS G |
| AFFILIATIONS | UNSW Sydney |
| ORCID | 0000-0002-1048-6396 |
| VERIFIED | Yes |
| TOTAL WORKS | 10 |
| TOTAL CITATIONS | 51 |
| WORKS AS AUTHOR | 10 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1967 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the Reach-C cohort
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Enhancing the detection and management of acute hepatitis C virus infection
Reactions to suffering of others under conditions of indirect responsibility
Reactions to suffering of others under conditions of indirect responsibility
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Enhancing the detection and management of acute hepatitis C virus infection
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the Reach-C cohort
Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Hepatitis C virus research (9 works) · Medicine (9 works) · Hepatitis C (7 works) · Hepatitis C virus (7 works) · Internal Medicine (7 works) · Virus (7 works) · Immunology (5 works) · Hepatitis B Virus Studies (4 works) · HIV, Drug Use, Sexual Risk (4 works) · Virology (4 works)